StockNews.AI
BBIO
StockNews.AI
1 min

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

1. BridgeBio will present ten posters at AHA Scientific Sessions 2025. 2. Acoramidis shows promise in reducing all-cause mortality in ATTR-CM patients. 3. Findings emphasize improved outcomes in cardiovascular health for treated patients. 4. Research indicates significant demographic disparities in treatment outcomes across the U.S. 5. Attruby is indicated for treating transthyretin-mediated amyloidosis (ATTR-CM).

7m saved
Insight
Article

FAQ

Why Bullish?

Acoramidis data revealing reduction in mortality could positively influence investor confidence, as similar situations have historically led to stock price increases for biopharmaceuticals with promising data.

How important is it?

The positive data presented on Acoramidis directly impacts BridgeBio's market perception and stock sentiment.

Why Short Term?

Immediate investor reaction to upcoming presentations can affect stock price in the near future, typically within weeks of significant announcements.

Related Companies

TFIPFENVO
November 03, 2025 07:30 ET  | Source: BridgeBio Pharma, Inc. PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orleans, LA from November 7 - 10, 2025. Moderated Digital Posters: Acoramidis Effect on All-Cause Mortality in Patients with p.V142I (V122I) Variant ATTR-CM: Findings from the ATTRibute-CM StudyPresenter: Marianna Fontana, M.D., University College London, UKDate/time: Saturday, November 8 at 3:15 pm CT Acoramidis Reduces All-Cause Mortality and First Cardiovascular Hospitalization in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results from the ATTRibute-CM StudyPresenter: Prem Soman, M.D., Ph.D., University of Pittsburgh School of Medicine, U.S.Date/time: Saturday, November 8 at 9:15 am CT Acoramidis Reduces All-Cause Mortality and Cardiovascular-Related Hospitalizations Through Month 42 in Transthyretin Amyloid Cardiomyopathy Across All Pre-specified Patient SubgroupsPresenter: Lily Stern, M.D., Cedars-Sinai Heart Institute, U.S.Date/time: Saturday, November 8 at 3:15 pm CT Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants with Transthyretin Amyloid Cardiomyopathy Compared with Placebo, Independent of Atrial Fibrillation StatusPresenter: Mathew Maurer, M.D., Columbia University Irving Medical Center, U.S.Date/time: Saturday, November 8 at 9:15 am CT Demographic Disparities in Tafamidis Treatment and Clinical Outcomes Across the United StatesPresenter: Nicole Cyrille-Superville, M.D., Atrium Health Sanger Heart & Vascular Institute Kenilworth, Charlotte, NC, U.S.Date/time: Saturday, November 8 at 12:15 pm CT Geographic Disparities in Transthyretin Amyloid Cardiomyopathy Prevalence in United States VeteransPresenter: Sandesh Dev, M.D., Southern Arizona VA Health Care System, U.S.Date/time: Saturday, November 8 at 3:15 pm CT Serum Transthyretin Levels at Day 28 are Associated with Cardiovascular Outcomes: Insights from the ATTRibute-CM StudyPresenter: Nitasha Sarswat, M.D., UChicago Medicine, U.S.Date/time: Sunday, November 9 at 3:15 pm CT Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients with Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at BaselinePresenter: Richard Cheng, M.D., University of Washington, Seattle, WA, U.S.Date/time: Sunday, November 9 at 3:15 pm CT Acoramidis Reduces the Risk of All-Cause Mortality and Cardiovascular-Related Hospitalization Compared with Placebo in Participants with Transthyretin Amyloid Cardiomyopathy and Early-Stage Heart Failure Regardless of Atrial Fibrillation History: Insights from ATTRibute-CM Presenter: Ronald Witteles, M.D., Stanford University School of Medicine, U.S.Date/time: Saturday, November 8 at 3:15 pm CT Vutrisiran Healthcare Resource Utilization, Costs, Discontinuation, and Mortality: A Retrospective Database Analysis Presenter: Nicole Bart, M.D., Ph.D., St Vincent's Hospital Sydney, AUDate/time: Monday, November 10 at 10:45 am CT About Attruby™ (acoramidis) INDICATIONAttruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. IMPORTANT SAFETY INFORMATION Adverse ReactionsDiarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively). About BridgeBioBridgeBio Pharma (BridgeBio; Nasdaq: BBIO) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube. BridgeBio Media Contact:Bubba Murarka, Executive Vice President, Corporate Developmentcontact@bridgebio.com   (650)-789-8220 BridgeBio Investor Contact:Chinmay Shukla, Senior Vice President, Strategic Financeir@bridgebio.com

Related News